Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Xyrem; Xywav (lower-sodium formulation with Ca/Mg/K salts) (1)

Analgesic (2) · Classic Psychedelic (1) · GABAB Agonist; Endogenous GHB receptor agonist (1) · Lysergamide (1) · Opioid (2) · Prodrug (1) · Research material (1)

Agonist at the metabotropic GABAB receptor and the endogenous γ-hydroxybutyrate (GHB) receptor. Produces deep sleep with increased slow-wave architecture, suppression of REM intrusion, and cataplexy reduction. (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of LSD; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000717-QINU`"', '"`UNIQ--vote-00000718-QINU`"', '"`UNIQ--vote-00000719-QINU`"' (1)

None (2) · 2.25 g at bedtime + 2.25 g 2.5–4 h later; titrate weekly to 6–9 g/night total (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 0.5 g/mL oral solution (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 9 g/night (1)

None (2) · Oral (must be taken in bed; effects within minutes) (1) · PO (only formulation marketed in the US). (1)

None (2) · 15–30 min (fasting) (1) · 30–60 min (PO) (1)

None (2) · 4–6 hours (1) · ~3 h per dose (twice-nightly schedule required) (1)

None (2) · 2.5–3 hours (1) · 30–60 min (1)

None (2) · ~25% (high first-pass) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1)

None (2) · Schedule III; REMS-restricted (Schedule I if outside the pharmaceutical channel, same molecule as illicit GHB) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)